FASLODEXTM is indicated as monotherapy for the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:
- Not previously treated with endocrine therapy, or
- With disease relapse on or after adjuvant antioestrogen therapy, or disease progression on antioestrogen therapy
Faslodex is also indicated in combination with palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.
- In pre- or perimenopausal women, the combination treatment with palbociclib should be combined with a luteinising hormone releasing hormone agonist.
FASLODEXTM 250mg solution for injection (fulvestrant)
Consult Summary of Product Characteristics before prescribing.
Legal category POM. Marketing Authorisation number EU/1/03/269/002 Presentation & Basic NHS cost 2 x 5 ml pre-filled syringes: £522.41 Marketing Authorisation Holder AstraZeneca AB, SE-151 85 Sodertalje, Sweden. SK10 2NA, UK. Further information is available from AstraZeneca UK Limited, 600 Capability Green, Luton, LU1 3LU, UK.
FASLODEXTM is a trade mark of the AstraZeneca group of companies. SAFETYGLIDE is a trade mark of Becton Dickinson and Company. Date of preparation 09/2018. ONC 18 0024.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to AstraZeneca on 0800 783 0033.